ArticleFrontiers in medicine2026
Novel diagnostic approaches and therapeutic management of mucormycosis: insights from a retrospective monocentric cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Mechanisms of Mucormycosis Pathogenesis: Host-Pathogen Interactions and Immune Evasion.Pathogens (Basel, Switzerland) · 2026Review
- Case Report: A diabetic ketoacidosis in adolescents complicated with rhino-orbital-cerebral mucormycosis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucormycosis is a rare, opportunistic fungal infection with high mortality rates, predominantly affecting immunocompromised patients. Its management is challenging due to diagnostic complexity and limited therapeutic options. Methods: This retrospective cohort study analyzed 21 cases of mucormycosis diagnosed at the University Hospital of Liège between July 2018 and August 2023. Clinical, microbiological, and radiological data were evaluated to identify risk factors, treatment modalities, and outcomes. Results: Hematological malignancies (82%) and immunosuppressive therapy (53%) were the most common risk factors. Pulmonary involvement occurred in 94% of cases. Liposomal Amphotericin B was the most frequently used antifungal therapy, and surgery improved outcomes in 50% of cases when it was performed. Despite these measures, the mortality rate on day 84 remained significant at 35%. Conclusion: This study underscores the challenges of managing mucormycosis in immunocompromised patients. The high mortality rate emphasizes the importance of early diagnosis, tailored antifungal therapy, and standardized treatment protocols to improve survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.